TBF1.F - Canntab Therapeutics Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.6200
0.0000 (0.00%)
As of 8:00AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close0.6200
Open0.6200
Bid0.6150 x 0
Ask0.6450 x 0
Day's Range0.6200 - 0.6200
52 Week Range0.1590 - 0.6200
Volume1,630
Avg. Volume56
Market Cap20.199M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
    CNW Group

    Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement

    TORONTO, June 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS.TO - News)(OTCQX:MEDIF - News)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products. Orders under the agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.